ClinicalTrials.gg
Enrolling by invitationNCT07734415Updated Jul 29, 2026

Long-term Safety and Efficacy Evaluation of IMG-007 in Participants With Moderate-to-Severe Atopic Dermatitis

A Phase 2 interventional study of IMG-007 in Atopic Dermatitis, Atopic Dermatitis Eczema and Eczema, sponsored by Inmagene LLC. Enrolling by invitation at 23 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-07-29.

Sponsored by Inmagene LLC · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
400
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 639 studies in Dermatitis, Atopic with a site in United States — 78 open to participants now, 117 under way, 18 of them phase 3. Dermatitis, Atopic · United States.

Planned enrollment
82nd of 544
400 · median 96
Started
2026
with 28 others
Phase 2
202 of 639
18 open now
Primary completion
2028-03
later than 78 of 115 live
Registered
628th of 639
by date

Among the 639 studies in Dermatitis, Atopic with a site in United States, this one is the 82nd largest by planned enrollment of the 544 interventional ones that give a count, is one of 29 that started in 2026, is one of 202 in phase 2, reaches primary completion later than 78 of the 115 other live ones, and was the 628th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

78 of the 639 studies in Dermatitis, Atopic with a site in United States are open now. Recruiting first, the newest first:

73 more — sign in →

All 78 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 639 studies in Dermatitis, Atopic with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety and efficacy of long-term treatment with IMG-007 in participants with moderate-to-severe atopic dermatitis (AD)

03

Conditions studied

  • Atopic Dermatitis
  • Atopic Dermatitis Eczema
  • Eczema

Keywords

  • IMG-007
  • Atopic Dermatitis
  • Dermatitis, Atopic
  • Dermatitis
  • Eczema
  • Skin Diseases
  • Immune System Diseases
  • Dermatologic Agents
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Enrolling by invitation participants with moderate to severe AD who have completed IMG-007-203

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
400 participants (estimated)

Study arms

  • Experimental
    IMG-007 Dose

    Subcutaneous injection as per protocol.

    Drug: IMG-007

Interventions

  • Participants will receive IMG-007 subcutaneously.

06

What researchers measure

Primary outcomes

  1. Evaluate the safety of long-term treatment with IMG-007 in participants with moderate-to-severe atopic dermatitis

    Incidence and severity of TEAEs, including treatment-emergent SAEs, AESIs, and AEs leading to discontinuation

    Time frame: Baseline, Week 44

Secondary outcomes

  1. Characterize the safety of long-term treatment with IMG-007 based on body temperature (Celsius)

    Time frame: Baseline, Week 44

  2. Characterize the safety of long-term treatment with IMG-007 based on pulse rate (beats per minute)

    Time frame: Baseline, Week 44

  3. Characterize the safety of long-term treatment with IMG-007 based on respiratory rate (breaths per minute)

    Time frame: Baseline, Week 44

  4. Characterize the safety of long-term treatment with IMG-007 based on blood pressure (systolic and diastolic) (mmHg)

    Time frame: Baseline, Week 44

  5. Number of Participants With Clinically Significant Abnormal (defined by rate, rhythm, morphology, and conduction abnormalities) ECG Findings (unit is number of participants).

    Time frame: Baseline, Week 44

  6. Characterize the safety of long-term treatment with IMG-007, as assessed by hematology

    Time frame: Baseline, Week 44

  7. Characterize the safety of long-term treatment with IMG-007, as assessed by blood chemistry

    Time frame: Baseline, Week 44

  8. Characterize the safety of long-term treatment with IMG-007, as assessed by urinalysis

    Time frame: Baseline, Week 44

  9. Evaluate the effect of long-term treatment with IMG-007 on disease activity as assessed by Eczema Area and Severity Index (EASI)

    Time frame: Baseline, Week 44

  10. Evaluate the effect of long-term treatment with IMG-007 on disease activity as assessed by Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD)

    Time frame: Baseline, Week 44

07

Study locations

23 sites
  • Inmagene Site 1
    Lancaster, California 93534, United States
  • Inmagene Site 23
    Los Angeles, California 90095, United States
  • Inmagene Site 19
    Ocala, Florida 34470, United States
  • Inmagene Site 4
    Tampa, Florida 33609, United States
  • Inmagene Site 2
    Rolling Meadows, Illinois 60008, United States
  • Inmagene Site 6
    Kew Gardens, New York 11415, United States
  • Inmagene Site 21
    New York, New York 10029, United States
  • Inmagene Site 11
    Woodbury, New York 11797, United States
  • Inmagene Site 20
    Charlotte, North Carolina 28277, United States
  • Inmagene Site 10
    Fargo, North Dakota 58103, United States
  • Inmagene Site 9
    Columbus, Ohio 43213, United States
  • Inmagene Site 5
    Mayfield Heights, Ohio 44124, United States
  • Inmagene Site 3
    Portland, Oregon 97210, United States
  • Inmagene Site 12
    Anderson, South Carolina 29621, United States
  • Inmagene Site 8
    Southlake, Texas 76092, United States
  • Inmagene Site 7
    Burien, Washington 698168, United States
  • Inmagene Site 15
    Surrey, British Columbia V3R 6A7, Canada
  • Inmagene Site 22
    Vancouver, British Columbia V6H 4B1, Canada
  • Inmagene Site 17
    Greater Sudbury, Ontario P3C 1X8, Canada
  • Inmagene Site 13
    Mississauga, Ontario L4Y 4C5, Canada
  • Inmagene Site 18
    North Bay, Ontario P1B 3Z7, Canada
  • Inmagene Site 14
    Montreal, Quebec H2X 2V1, Canada
  • Inmagene Site 16
    Saskatoon, Saskatchewan S7K 2C1, Canada
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Mar 2028, 21 months after the start.

Of 196 industry-sponsored phase 2 interventional studies under Dermatitis, Atopic, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 17. This study's planned 21 months is above that.

Counting every sponsor, half of 224 studies reached it within 14 months; a quarter within 10 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 11, 2026
First posted
Jul 29, 2026
StartActual
Jun 5, 2026
Primary completionEst.
Mar 2028
CompletionEst.
Mar 2028
Last update
Jul 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07734415
Lead sponsor
Inmagene LLC
Responsible party
Sponsor
First posted
Jul 29, 2026
Start date
Jun 5, 2026
Primary completion
Mar 2028 (estimated)
Completion
Mar 2028 (estimated)
Last update
Jul 29, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: IMG-007

Start the discussion